This clinical trial includes four cohorts: hu14.18-IL2 alone, with radiation therapy, after radiation therapy and in combination with nivolumab, and after radiation therapy and in combination with nivolumab and ipilimumab in patients with pretreated advanced or unresectable melanoma. This evidence concerns the gene IL2 and melanoma.